On March 16, 2023 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), reported that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022 (Press release, Innate Pharma, MAR 16, 2023, View Source [SID1234628900]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Speakers during the call will be:

Mondher Mahjoubi, Chief Executive Officer
Joyson Karakunnel, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Details for the Virtual Event

The live webcast will be available at the following link:
View Source

Participants may also join via telephone using the following registration link: View Source

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.